CHRONOTHERAPEUTIC DILTIAZEM FORMULATIONS AND THE ADMINISTRATION THEREOF

Number of patents in Portfolio can not be more than 2000

United States of America Patent

SERIAL NO

11952343

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

A method of treating or preventing myocardial ischemia in a patient in need thereof comprising administration of a controlled-release Galenical preparation of pharmaceutically acceptable Diltiazem including the pharmaceutically acceptable salts thereof, suitable for evening dosing every 24 hours containing from about 180 mg to about 420 mg of the form of Diltiazem associated with excipients to provide controlled (sustained) release of the form of Diltiazem for providing a Cmax of diltiazem in the blood at between about 10 hours and about 17 hours after administration, the preparation comprising the form of Diltiazem in oral sustained-release dosage form in which the Diltiazem is adapted to be released after administration over a prolonged period of time and exhibits when given to humans (i) a higher bioavailability when given at night compared to when given in the morning without food according to FDA guidelines or criteria and (ii) bioequivalence when given in the morning with and without food according to the same FDA guidelines or criteria.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
BIOVAIL LABORATORIES INTERNATIONAL S R LWELCHES CHRIST CHURCH BB17154

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
ALBERT, Kenneth Stephen Mt. Kisco , US 4 46
Gana, Theophilus Jones Leesburg , US 2 23
Maes, Paul Potomac , US 52 1315

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation